Search

everythinglearnresearchcommunity

for

Search:↓

A person with low-density hair likely experiencing diffuse thinning. Suggested treatments include finasteride, minoxidil, and dutasteride.

Azelaic acid is discussed as a DHT inhibitor with no reported sexual side effects, but its effectiveness and absorption as a topical treatment are questioned. The user is interested in azelaic acid due to concerns about finasteride affecting penile health.

The conversation discusses skepticism about Breezula, a hair loss treatment, with the consensus that it's not a miracle cure but a maintenance drug that may work well with finasteride. Some users report side effects from finasteride, like sexual dysfunction, while hoping for better results from Breezula or RU58841 without such side effects.

A female user is seeking feedback on using topical minoxidil on eyebrows due to eyebrow loss, as oral minoxidil hasn't worked and they avoid Latisse due to potential fat loss.

Blocking DHT is not a cure for hair loss; instead, altering how scalp follicles respond to DHT might be more effective. Current treatments like topical finasteride and minoxidil are temporary solutions, and future approaches may involve gene therapy and bioengineering to change follicle behavior.

The user shared progress pictures showing significant hair regrowth using Minoxidil and a dermapen, expressing concerns about potential side effects of finasteride due to low testosterone levels. Another user reported increased testosterone and no side effects from finasteride, with improved libido.

Finasteride is recommended for hair loss, while biotin is considered ineffective and unnecessary. Minoxidil is also suggested, and biotin pills are preferred over injections due to cost and absorption concerns.

People are frustrated with hair loss treatments like finasteride, minoxidil, and dutasteride, with mixed results and side effects. Some users suggest trying different combinations or doses, while others express disappointment and hope for a cure.

A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.

The conversation is about which blood markers to test before starting a 5-AR inhibitor for hair loss. The user mentions already testing Total T, Free T, SHBG, Estradiol, Haematocrit, Red blood cell count, and White cell count, and asks if DHT or additional markers are needed.

A 26-year-old male started minoxidil treatment for male-pattern baldness and saw significant regrowth in three months. He is considering finasteride but is hesitant due to potential side effects.

Minoxidil's effectiveness varies due to genetic differences in the SULT1A1 enzyme, affecting how well it converts to its active form, minoxidil sulfate. Hyper-responders may experience rapid hair growth and increased side effects, such as pericardial effusion, even at low doses.

The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.

People discussed hair loss treatments, including finasteride, minoxidil, and microneedling, with varying results and concerns about genetics and hormone levels. Some users shared personal experiences with medication dosages and side effects, while others mentioned the impact of stress on hair loss.

The conversation discusses whether not masturbating (semen retention) affects hair loss, with opinions varying but generally dismissing the idea. Some participants mention using hair loss treatments like Minoxidil, Finasteride, and RU58841, but the effectiveness and relation to prolactin levels in the scalp are debated.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

Gym and creatine can cause hair loss by increasing testosterone and androgenic activity. DHT blockers may help some, while others need androgen suppression with topical AA like RU or Pyri.

The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.

The user switched from topical to oral finasteride and minoxidil for hair loss and experienced swelling and sensitivity in the left chest area. They are concerned about these symptoms but noticed improvement after skipping a dose.

The conversation discusses hair loss treatments, focusing on iron supplements for low ferritin levels and considering finasteride and minoxidil if thinning persists. There is debate over starting with finasteride versus dutasteride, with some users advocating for dutasteride due to its potency, while others caution about potential side effects.

The user experienced significant hair regrowth with finasteride but noticed recent hair thinning, possibly due to nutrient deficiencies and weight loss. They plan to add microneedling and consider switching to dutasteride.

A 29-year-old male has been taking 1mg finasteride daily for 8 months and using 5% minoxidil with tretinoin but is experiencing increased hair shedding and higher DHT levels. He is concerned about the effectiveness of finasteride and has noticed low libido and occasional ED.

Elevated PGD2 levels in bald scalp tissue may contribute to hair loss, and treatments like castor oil, finasteride, and minoxidil are discussed as potential solutions. Some users explore alternatives like oral castor oil and cetirizine for those who cannot use finasteride.

A 25-year-old male using Dutasteride, oral Minoxidil, and Ketoconazole shampoo is experiencing increased hair shedding and vellus hair growth along the hairline. Concerns are raised about whether this is a seasonal shed or a potential setback.

High prolactin levels may contribute to hair loss, and some users suggest supplements like mucuna pruriens, vitamin B6, vitamin E, L-Tyrosine, L-Theanine, DIM, and Zinc to lower prolactin. Lifestyle changes to increase dopamine, such as reducing screen time and stress, are also recommended.

A user humorously suggests an extreme hair loss treatment regimen involving multiple medications and therapies, including Dutasteride, Minoxidil, RU58841, and others, claiming it would prevent hair loss but with potential side effects like gynecomastia. The conversation highlights concerns about safety, side effects, and the effectiveness of such a comprehensive approach.

Dutasteride and finasteride have similar risks of sexual dysfunction for treating androgenetic alopecia. Users experience varying side effects, indicating individual differences in drug reactions.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

The conversation is about whether testing for free DHT is necessary before starting Finasteride for hair loss, despite having other hormone tests available. One person suggests that genetic response to DHT is more important than DHT levels and advises starting Finasteride without the free DHT test.

The user is experiencing ongoing hair loss despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, cyproterone acetate, transdermal estradiol, and topical bicalutamide. They suspect cyproterone acetate may be worsening their hair loss and are considering switching to injection monotherapy.